Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR3A | P46098 | 7/20 | 0.56 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.56 |
| ▸ | LMNA | P02545 | 4/20 | 0.45 |
| ▸ | IDO1 | P14902 | 1/20 | 0.43 |
| ▸ | MAOA | P21397 | 1/20 | 0.43 |
| ▸ | MAOB | P27338 | 1/20 | 0.43 |
| ▸ | HTR2B | P41595 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
| ▸ | PARP1 | P09874 | 1/20 | 0.39 |
| ▸ | TOP2A | P11388 | 2/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.37 |
| ▸ | THRB | P10828 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4317333 | 0.97 | HTR3A (0.53) | HTR3AKCNH2LMNAIDO1MAOA | |
| SCHEMBL4317274 | 0.96 | HTR3A (0.52) | HTR3AKCNH2LMNAIDO1MAOA | |
| SCHEMBL4315476 | 0.94 | HTR3A (0.57) | HTR3AKCNH2LMNAIDO1MAOA | |
| SCHEMBL4309668 | 0.89 | HTR3A (0.50) | HTR3AKCNH2LMNAIDO1MAOA | |
| SCHEMBL4305393 | 0.83 | LMNA (0.53) | HTR3AKCNH2LMNAHTR2BALDH1A1 | |
| SCHEMBL4315550 | 0.79 | HTR3A (0.44) | HTR3AKCNH2IDO1MAOAMAOB | |
| SCHEMBL4305254 | 0.78 | SMN1; SMN2 (0.51) | HTR3AKCNH2LMNAHTR2BALDH1A1 | |
| SCHEMBL4318157 | 0.77 | HTR3A (0.48) | HTR3AKCNH2PARP1 | |
| SCHEMBL4313234 | 0.75 | HTR3A (0.92) | HTR3AKCNH2 | |
| SCHEMBL4313238 | 0.75 | HTR3A (0.92) | HTR3AKCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8278301-B2 | 2-alkylbenzoxazole carboxamides as 5HT3 modulators | ALBANY MOLECULAR RESEARCH, INC. (US) | 2012-10-02 | — | — | US | disclosed |
| US-20090227576-A1 | 2-ALKYLBENZOXAZOLE CARBOXAMIDES AS 5HT3 MODULATORS | ALBANY MOLECULAR RESEARCH, INC. (US) | 2009-09-10 | — | — | US | disclosed |
| US-7553846-B2 | 2-alkylbenzoxazole carboxamides as 5-HT3 modulators | ALBANY MOLECULAR RESEARCH, INC. (US) | 2009-06-30 | — | — | US | disclosed |
| US-20080214601-A1 | 2-ALKYLBENZOXAZOLE CARBOXAMIDES AS 5HT3 MODULATORS | AMR TECHNOLOGY, INC. (US) | 2008-09-04 | — | — | US | disclosed |
| WO-2008019363-A2 | 2-ALKYLBENZOXAZOLE CARBOXAMIDES AS 5HT3 MODULATORS | ALBANY MOLECULAR RESEARCH, INC. (US) | 2008-02-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090227576-A1 | 2-ALKYLBENZOXAZOLE CARBOXAMIDES AS 5HT3 MODULATORS | HTR3E, HTR3C, HTR3A | HTR3A 3/4885KCNH2 1161/4885LMNA 2774/4885 |
| US-20080214601-A1 | 2-ALKYLBENZOXAZOLE CARBOXAMIDES AS 5HT3 MODULATORS | HTR3E, HTR3C, HTR3A | HTR3A 3/4885KCNH2 1161/4885LMNA 2774/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.